| Literature DB >> 21542061 |
Tamuno Alfred1, Yoav Ben-Shlomo, Rachel Cooper, Rebecca Hardy, Cyrus Cooper, Ian J Deary, David Gunnell, Sarah E Harris, Meena Kumari, Richard M Martin, Colin N Moran, Yannis P Pitsiladis, Susan M Ring, Avan Aihie Sayer, George Davey Smith, John M Starr, Diana Kuh, Ian N M Day.
Abstract
The ACTN3 R577X (rs1815739) genotype has been associated with athletic status and muscle phenotypes, although not consistently. Our objective was to conduct a meta-analysis of the published literature on athletic status and investigate its associations with physical capability in several new population-based studies. Relevant data were extracted from studies in the literature, comparing genotype frequencies between controls and sprint/power and endurance athletes. For life course physical capability, data were used from two studies of adolescents and seven studies in the Healthy Ageing across the Life Course (HALCyon) collaborative research program, involving individuals aged between 53 and 90+ years. We found evidence from the published literature to support the hypothesis that in Europeans the RR genotype is more common among sprint/power athletes compared with their controls. There is currently no evidence that the X allele is advantageous to endurance athleticism. We found no association between R577X and grip strength (P = 0.09, n = 7,672 in males; P = 0.90, n = 7,839 in females), standing balance, timed get up and go, or chair rises in our studies of physical capability. The ACTN3 R577X genotype is associated with sprint/power athletic status in Europeans, but does not appear to be associated with objective measures of physical capability in the general population.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21542061 PMCID: PMC3174315 DOI: 10.1002/humu.21526
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878
Summary of Sex, Age, and ACTN3 R577X Minor Allele Frequencies by Cohort
| Cohort | Age | Male, % | MAF | Total | Physical capability measures included in present analysis |
|---|---|---|---|---|---|
| ALSPAC | 11 (10–13) | 51 | 0.44 | 2,967 | Grip strength |
| Eureka | 15 (11–18) | 53 | 0.42 | 992 | Grip strength |
| NSHD | 53 | 50 | 0.44 | 2,595 | Grip strength, standing balance, |
| ELSA | 65 (52–90+) | 46 | 0.44 | 5,435 | Grip strength, standing balance, |
| HCS | 66 (59–73) | 53 | 0.43 | 2,831 | Grip strength, standing balance, |
| HAS | 67 (63–73) | 61 | 0.42 | 508 | Grip strength, TGUG, timed chair rises |
| Boyd Orr | 70 (64–82) | 46 | 0.46 | 684 | Standing balance, |
| CaPS | 73 (65–83) | 100 | 0.42 | 1,309 | Standing balance, |
| LBC1921 | 79 (77–80) | 41 | 0.45 | 514 | Grip strength, timed walk |
| Total | 60 (10–90+) | 53 | 0.43 | 17,835 |
Age at phase from which the majority of variables are taken.
Flamingo in NSHD, HCS, HAS, Boyd Orr, and CaPS; side-by-side, semitandem, and full tandem in ELSA.
2.44 m (8 feet) in ELSA, 6 m in LBC1921.
Five rises in ELSA, HCS, and HAS, 10 rises in NSHD. Genotype frequencies by sex presented in Suppl. Table S2. Minor allele: X. TGUG, timed get up and go.
Figure 1Associations between ACTN3 R577X genotype (RR vs. RX + XX) and sprint/power athletic status from the literature. Arrow indicates the confidence interval extends beyond the plot axis. Stratified by ancestral group. Effects are given as odds ratios (OR) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D + L: DerSimonian & Laird, random effects model.
Figure 2Associations between ACTN3 R577X genotype (XX vs. RX + RR) and endurance athletic status from the literature. Arrow indicates the confidence interval extends beyond the plot axis. Stratified by ancestral group. Effects are given as odds ratios (OR) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D + L: DerSimonian & Laird, random effects model.
Figure 3Associations between ACTN3 R577X genotype and grip strength. Studies ordered by overall median age. Effects are given as per X allele change in grip strength (z-score) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D + L: DerSimonian & Laird, random effects model.
Figure 4Associations between ACTN3 R577X genotype and timed get up and go/walk. Studies ordered by overall median age. Effects are given as per X allele change in timed get up and go or walk (z-score) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D + L: DerSimonian & Laird, random effects model.
Figure 6Associations between ACTN3 R577X genotype and poor standing balance. Poor standing balance defined as inability to complete 30 sec, or 5 sec of the full tandem in ELSA. Studies ordered by overall median age. Effects are given as poor balance odds ratio (OR) per X allele and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D + L: DerSimonian & Laird, random effects model.